MRKR (Marker Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is Marker Therapeutics Days Payable?

Marker Therapeutics MRKR +12.84% 30 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates MRKR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 700 Biotechnology companies, Marker Therapeutics ranks worse than 142857% on this metric.

Marker Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $1.15 Mil. Marker Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Marker Therapeutics's Days Payable or its related term are showing as below:

MRKR's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Marker Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Marker Therapeutics Days Payable Related Terms

Marker Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Days Payable Chart

Marker Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Marker Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MRKR vs PLUR, VYNE, LGVN: Days Payable Comparison

For the Biotechnology subindustry, Marker Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Days Payable falls into.

Save Embed

30GF Score

Marker Therapeutics Inc MRKR

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Marker Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Marker Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (1.066	+	0.794)	/	2 )	/	0	*	365
=	0.93					/	0	*	365
=	N/A

Marker Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.794	+	1.5)	/	2 )	/	0	*	365 / 4
=	1.147					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Marker Therapeutics (MRKR) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Marker Therapeutics and its competitors. According to the industry distribution chart, Marker Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry.

Is Marker Therapeutics' Days Payable too high?

Marker Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Marker Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marker Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Marker Therapeutics' Days Payable compare to PLUR and VYNE?

According to the Biotechnology industry distribution chart, Marker Therapeutics ranks #999999 out of 700 companies for Days Payable. This places Marker Therapeutics in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Marker Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marker Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Marker Therapeutics stock overvalued right now?

Marker Therapeutics (MRKR) has a current Days Payable of 0.00. The current Days Payable is 0.00. Marker Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Marker Therapeutics (MRKR), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PLUR VYNE LGVN ALLR NCEL LPCN PTN CLRB SKYE PLRZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges GX1:Germany

Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021

Website https://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

30GF Score

Get the complete analysis for MRKR

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.67

Price

View MRKR Analysis

See Days Payable data for all stocks →